Company Information

  

Address: SUITE 720-999 WEST BROADWAY  
City: VANCOUVER 
State:  
Zip Code: V5Z 1K5 
Telephone: (604) 629-5989 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

DelMar Pharmaceuticals, Inc. (the "Company") is a clinical stage drug development company with a focus on the treatment of cancer. Our mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, modern therapy. Upon obtaining regulatory approval, we intend to commercialize VAL-083 for the treatment of orphan cancer indications such as refractory GBM. We may also seek collaborative development and commercialization partnerships to accelerate and expand the development of VAL-083 in newly diagnosed GBM and other non-orphan cancer indications.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.74NAN/E
03/20170.85NA4.94
12/20160.77NA4.14
09/20160.89NA6.80
06/20160.81NA9.69
03/20162.24NA1.54

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.22Total Liab/Total Assets0.17
Net Inc/Total Assets-1.02Total Liab/Inv Cap0.20
Net Inc/Inv Cap-1.23Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.01
Cash Flow/Net SalesNALTD/Equity0.00
SG&A/NetSalesNATotal Debt/Equity0.01
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.03
Inventory TurnoverNACurrent Ratio6.03
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 0.73 0.70 0.57 1.32
Operating Income -2.80 -1.78 -1.69 -2.05
Interest Exp NA NA NA NA
Pretax Income -2.60 -1.87 -1.32 -2.29
Other Income 0.19 -0.08 0.37 -0.24
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.60 -1.87 -1.32 -2.29

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 6.59 2.10 3.42 4.80
Receivables - Total 0.08 0.07 0.02 0.04
Inventories - Total NA NA NA NA
Total Current Assets 7.87 2.32 3.57 5.01
Net Property, Plant & Equipment NA NA NA NA
Total Assets 7.91 2.34 3.59 5.05
Liabilities        
Accounts Payable 1.27 0.86 0.72 0.48
Debt in Current Liabilities 0.03 0.16 NA NA
Total Current Liabilities 1.30 1.02 0.72 0.48
Long-Term Debt 0.03 0.09 0.17 0.59
Total Liabilities 1.33 1.11 0.89 1.07
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 6.43 6.47 6.49 6.57
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -41.12 -38.40 -36.32 -34.84
Treasury Stock NA NA NA NA
Total Stockholders' Equity 6.58 1.23 2.70 3.97
Total Liabilities and Stockholders' Equity 7.91 2.34 3.59 5.05

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -3.45 -1.51 -1.45 -1.61
Net Cash Provided by Investing Activities -0.02 0.00 0.00 NA
Net Cash Provided by Financing Activities 7.96 0.19 0.07 0.25

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20120.00-0.02--
06/20140.006.36--
06/20150.00-4.35--
06/20160.00-8.860.81
06/20170.00-8.08-0.74
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1771,8628.64




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.